[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100467515":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":29,"centralContacts":34,"locations":39,"responsibleParty":54,"collaborators":11,"id":56,"slug":57,"hasResults":58,"nctId":59,"briefTitle":60,"officialTitle":61,"acronym":11,"eligibilityCriteria":62,"healthyVolunteers":58,"sex":63,"minAge":64,"maxAge":11,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":74,"overallStatus":79,"whyStopped":11,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Jiangsu Hansoh Pharmaceutical Co., Ltd.","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Flumatinib mesylate tablets","EXPERIMENTAL",null,[13],"Drug: Flumatinib",{"label":15,"type":16,"description":11,"interventionNames":17},"Imatinib mesylate tablets","ACTIVE_COMPARATOR",[18],"Drug: Imatinib",[20,25],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":11},"DRUG","Flumatinib","Flumatinib 600mg orally daily",[9],{"type":21,"name":26,"description":27,"armGroupLabels":28,"otherNames":11},"Imatinib","Imatinib 400mg orally daily (Reference drug instructions)",[15],[30],{"name":31,"affiliation":32,"role":33},"Jun Ma","Institute of Hematology and Oncology, Harbin The First Hospital","PRINCIPAL_INVESTIGATOR",[35],{"name":31,"role":36,"phone":37,"phoneExt":11,"email":38},"CONTACT","13304518000","majun0322@126.com",[40],{"facility":32,"status":11,"city":41,"state":42,"zip":43,"country":44,"countryCode":45,"cosmosGeoPoint":46,"geoPoint":51,"contacts":52},"Harbin","Heilongjiang","201203","China","CN",{"type":47,"coordinates":48},"Point",[49,50],126.65,45.75,{"lat":50,"lon":49},[53],{"name":31,"role":36,"phone":37,"phoneExt":11,"email":38},{"type":55,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100467515","phase-4-a-real-world-study-of-the-efficacy-and-safety-of-flumatinib-versus-imatinib-in-patients-with-newly-diagnosed-chronic-myeloid-leukemia-in-chronic-phase-100467515",false,"NCT05367765","A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase","Evaluating the Efficacy and Safety of Flumatinib Versus Imatinib for in Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML)-in Chronic Phase (CP): A Multicenter, Open-label, Real World Study","Inclusion Criteria:\n\n1. Men or women aged more than or equal to (≥) 18 years.\n2. Patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase (Ph+ CML-CP) within 6 months of diagnosis..\n3. Eastern Cooperative Oncology Group (ECOG) performance status: 0\\~2.\n4. Signed and dated Informed Consent Form.\n\nExclusion Criteria:\n\n1. Patients with previously documented T315I mutation.\n2. Received BCR-ABL TKI(s) treatment before enrollment.\n3. Any treatment with anti-CML therapy over 2 weeks or hematopoietic stem cell transplantation before enrollment\n4. Participated in other clinical trials that might affect the efficacy and safety of CML during this study.\n5. Pregnant or lactating female.","ALL","18 Years",{"count":66,"type":67},2400,"ESTIMATED","INTERVENTIONAL",[70],"PHASE4","Flumatinib is an orally available TKI with high selectivity and potency against BCR-ABL1 kinase. It's a multi-center, open-label, real world study to explore the efficacy and safety of Flumatinib versus Imatinib as the first line therapy in patients with chronic myleiod leukemia(CML) in chronic phase(CP).",[73],"CML, Chronic Phase",[75,22,76,77,78],"Chronic Myeloid Leukemia","BCR-ABL TKI","Real World","Prospective","NOT_YET_RECRUITING","2022-05-05",{"date":82,"type":83},"2022-05-10","ACTUAL",{"date":85,"type":67},"2022-04-30",{"date":87,"type":67},"2028-04-30",{"name":5,"class":6},1]